GLP1R and myeloid sarcoma: In terms of MS, GLP‐1R agonists and DPP‐4 inhibitors have been reported to have therapeutic efficacy on neuroinflammation and demyelination on EAE model,26, 27 cuprizone model28 in vivo, and BV2 model29 in vitro through regulating peripheral T helper (Th) cell proportions, stabilize microglia, and reduce pro‐inflammatory cytokines.